The Updated ASCO 340B Policy Statement: A Detailed Read for Covered Entities

Written By Girish Kaimal

What the statement actually proposes

Published in JCO Oncology Practice in May 2026 (Polite et al.), the statement leaves the existing hospital DSH eligibility formula untouched and builds its new machinery around independent oncology practices. The centerpiece is a proposed Indigent Care Ratio (ICR) — Medicaid, uninsured, and dual-eligible visits divided by total visits under a single tax ID — with practices scoring above 11.75% (mirroring the hospital DSH threshold) becoming eligible for 340B. Around that access expansion, the statement bolts a reform framework aimed squarely at covered-entity conduct: a restriction on using savings for capital expenditure, a leadership attestation, IRS 501(r) as a condition of participation, mandatory reporting, and an expanded civil monetary penalty regime.

Lets start with what ASCO gets right

A credible critique has to begin by conceding the diagnosis, because much of it is correct. The reform impulse is responding to genuine failures, and pretending otherwise only makes the defense of the program sound reflexive.

Patient affordability is a real problem. Some hospitals bill uninsured patients off the chargemaster and pursue aggressive collections; charity care is unevenly distributed across covered entities; and patients do not reliably see the benefit of a discount their provider received. Contract pharmacy economics are a real problem — fees paid to pharmacies and third-party administrators can capture a large share of program value, money that leaks to intermediaries rather than reaching patients or safety-net care. And transparency is a real problem: from the outside, it is genuinely difficult to see how a given entity uses its savings, which corrodes trust in the program as a whole. ASCO is also right that the current inpatient-based eligibility test arbitrarily excludes community oncologists who serve the very same low-income patients.

So when ASCO argues that covered entities should be able to document their eligibility, show measurable service to underserved populations, reduce patient out-of-pocket costs, and report on their use of savings, the goals are reasonable. Several specific planks deserve outright support: preserving the patient definition against efforts to exclude insured patients, defending the right to engage multiple contract pharmacies against manufacturer restrictions, and repealing the orphan-drug exclusion that burdens critical access hospitals.

The disagreement that follows is not with the diagnosis. It is with the remedy — its vagueness, its enforcement design, and the precedent it sets. The problems are real; ASCO's quantification of them is arguable; and these particular mechanisms are the wrong fix.

The issues, in detail

1. A restriction on using 340B savings for capital expenditure. The statement would prohibit covered entities from applying 340B savings to new construction, major renovations, or service-line expansion unless directly tied to 340B-eligible populations. Congress has deliberately declined to restrict the use of 340B savings since 1992, recognizing that safety-net providers use program value to cross-subsidize money-losing service lines and absorb uncompensated care. Converting that silence into a federally enforced spending restriction is the single most consequential ask in the document, and it rests on no statutory foundation.

2. A leadership attestation requirement. Paired with the spending restriction, the statement would require system leadership to verify and attest that specific 340B savings were used appropriately for patient care. This imposes a savings-tracing standard that is operationally difficult for any integrated system and creates personal accountability exposure for named executives — a meaningful escalation from current reporting norms.

3. Importing IRS 501(r) as a condition of participation. The statement would require any institution accessing 340B — explicitly including hospitals, regardless of tax status — to substantially meet the 501(r) financial-assistance standards (written financial assistance policy, public posting, multilingual application, reasonable-efforts screening before extraordinary collections). For nonprofit hospitals this largely duplicates existing obligations, but it converts a tax-exemption requirement into a drug-pricing eligibility requirement, creating overlapping enforcement for conduct the IRS already governs.

4. A broadened civil monetary penalty regime. Current CMP authority is narrow and aimed at manufacturer overcharges. The statement would extend penalties to covered entities — up to ten times the unlawful revenue for excessive contract-pharmacy and TPA fees, plus new penalty categories for failures of transparency, patient-liability limitation, and use of savings.

5. Mandatory federal reporting. The statement would require reporting of purchases, acquisition costs, contract-pharmacy and TPA fees, and calculated savings to HHS. This is broadly consistent with the wave of state 340B transparency laws and should be anticipated regardless of this statement's fate, but it adds a standing analytics and compliance burden.

6. A narrowed patient-relationship standard. Post-Genesis, the statement endorses requiring an ongoing clinical relationship between patient and entity, with the drug tied to services the entity provided. This is a modest tightening relative to the expansive reading covered entities currently enjoy, and is most relevant to dispensing tied to loosely affiliated encounters and care-coordination arrangements.

The danger is the standard, not just the restriction

The sharpest risk in the package is not any single restriction. It is the vagueness of the standards that would trigger penalties. Read the operative language: savings must support "appropriate use" and "direct patient care"; capital projects must "demonstrably benefit" "underserved populations"; leadership must attest that savings were "appropriately utilized." None of these terms is defined — not in statute, and not in the statement.

A vague standard is tolerable when nothing turns on it. This one is wired directly to civil monetary penalties and a personal leadership attestation. That combination is the problem. When the standard is undefined and the penalty is real, the enforcer effectively writes the rule after the fact — a fair-notice and arbitrary-enforcement concern, and the mechanism by which a compliance regime quietly becomes a discretionary one. A covered entity cannot reliably comply with a standard whose meaning is set by an agency or a court only after the spending decision has been made. The rational response is not better compliance; it is under-investment — declining to deploy savings into exactly the community projects the program exists to fund, because no one can certify in advance that a regulator will later agree the use was "appropriate."

It is worth being precise about the one exception. "Excessive fees" is the only one of these terms the statement actually anchors, proposing to cap contract-pharmacy and TPA fees as a percentage of the commercial dispensing fee. That gives it a metric. The danger concentrates in the use-of-funds and attestation language, which carry the highest penalty exposure and the least definition. The distinction between a rule and a discretion is the whole ballgame, and on its most consequential terms the statement chooses discretion.

The deeper risk: ASCO is writing tomorrow's hospital test

The most strategically important feature of the statement is also the easiest to miss, because it is framed as help rather than threat.

ASCO is not attacking hospital eligibility. It explicitly leaves the DSH formula intact and excludes hospital-owned practices from the ICR. That is precisely what makes it effective. What the statement does instead is build the intellectual framework that a future reformer could apply to hospital outpatient departments. Two textual tells give it away: the statement asserts that hospital off-campus sites of care do not always reflect the same level of patient financial need, and the ICR requires every site under a single tax ID to be counted, expressly to prevent "site cherry-picking." That is the exact logic of a site-level indigent-care test.

Once that premise is accepted — that an outpatient site should independently demonstrate its own indigent-care mix — there is no principled stopping point at independent practices. The same ratio, the same denominator rule, pointed at hospital child sites and off-campus departments, becomes a tool to strip outpatient eligibility from systems that qualify today at the entity level. ASCO is not proposing that. It is making it thinkable, and citable, from a respected clinical platform.

And the framework is politically armored. A hospital that objects to it looks like it is opposing access for community oncologists who serve the poor — the sympathetic heart of the document. ASCO advances the premise while the only parties with reason to resist it are cast as the villains of the consolidation story. That is the provision with the longest tail. The capital-expenditure restriction is this year's problem; the eligibility framework is the next decade's.

What this looks like in practice

The abstract provisions land harder against concrete entities. Three illustrate how the same package cuts differently across the program.

A DSH hospital building a cancer center. A disproportionate-share system plans a new outpatient cancer center, with part of the capital underwritten by accumulated 340B margin — the cross-subsidy that has historically let safety-net systems build community capacity. Under the proposed restriction, savings cannot fund new construction or service-line expansion unless the build is directly tied to 340B-eligible populations, and leadership must personally attest to the use of those specific savings against a standard no one has defined. A routine, access-expanding project becomes a financing and compliance problem, and the very kind of community investment the program was meant to enable is curtailed. The irony is hard to miss: a cancer center that expands access is precisely the community benefit the statement says it wants.

A rural referral center keeping oncology local. An RRC (qualifying at the lower 8% threshold) applies 340B margin on infused oncology drugs to offset the structural losses of low-volume rural oncology, keeping a service line open in a community that would otherwise face a multi-hour drive to a metropolitan center. Shrink that spread — through Best Price and rebate-model pressure, or through use-of-funds rules that bar applying savings to sustain the line — and the service becomes unsustainable and closes. The local-access preservation the statement explicitly claims to protect is undermined by its own reforms.

A critical access hospital with mixed effects. A CAH gains real ground from the orphan-drug exclusion repeal, finally able to obtain 340B pricing on orphan drugs used off-label or for common conditions — a meaningful win for a small rural budget. But the same package layers on mandatory reporting and, if extended to all entities, attestation, 501(r), and transparency obligations. For a CAH running a skeleton pharmacy and finance team, the fixed cost of that compliance can erode or exceed the orphan-drug gain. The benefits accrue unevenly and the costs fall hardest on the smallest entities — the reform is regressive by entity size.

What the statement leaves out

The most telling gaps are economic. The statement, written by clinicians about how entities use 340B, never engages the manufacturer-side price mechanics that determine the size of program value or who ultimately finances it.

No gross-to-net analysis. The 340B ceiling price is, by formula, AMP minus the Medicaid unit rebate amount, and for branded drugs that rebate is driven by Best Price. Best Price therefore sets the 340B ceiling transitively. Manufacturers manage their entire gross-to-net waterfall to protect Best Price, and they defend net price by raising list — which pushes cost onto the coinsured and uninsured patients the statement claims to protect. None of the use-of-funds reforms touch the size of the spread or its financing. (Notably, CMS proposed mandatory discount "stacking" in its 2024 Medicaid Drug Rebate Program rule but declined to finalize it, leaving a future-rulemaking risk that would lower 340B ceilings if revived.)

No branded-versus-biosimilar asymmetry. An older single-source reference biologic carries a large rebate — basic plus an accumulated inflation penalty, now uncapped — driving its 340B ceiling toward zero and its spread very high. A biosimilar yields a thin spread by comparison. The result is a perverse inversion in which an entity can earn more absolute 340B margin on the expensive reference brand than on the cheaper biosimilar, so program economics can suppress biosimilar adoption — the opposite of system cost containment. For an oncology-specific statement, this omission is striking.

No site-of-care neutrality. The consolidation the statement decries is driven not by 340B alone but by 340B stacked on the hospital outpatient payment differential: acquire a practice, convert it to provider-based, and capture both the higher site-of-care reimbursement and the 340B discount on the same drug. The statement names the consolidation but never connects it to the payment differential that makes the acquisition math work — and stays silent on site-neutral payment, the one reform that would most directly address it.

Who pays, who benefits, who is harmed

The 340B spread — the gap between a covered entity's discounted acquisition cost and what it is reimbursed — is a transfer, and the debate is incomplete until you trace it. The statement frames the issue almost entirely as covered entities versus manufacturers and reformers. The parties with the largest financial stake are barely mentioned.

Who pays. Manufacturers book the discount as a deduction in their gross-to-net, but they defend net price by raising list. So the cost is substantially shifted downstream: to Medicare beneficiaries (Part B and Part D coinsurance is a percentage of list, not of the discounted price), to commercially insured patients in high-deductible plans, to uninsured patients billed off the chargemaster, to commercial payers and the self-funded employers behind them whose premiums reflect list-based net costs, and indirectly to taxpayers through higher federal spending. "Who pays for 340B" is not a clean manufacturer-only story — it is a diffuse charge spread across patients, employers, payers, and the public.

Who benefits. Covered entities capture the spread. For genuine safety-net providers, it funds uncompensated care, rural service lines, and community programs that would not otherwise survive. For others, it can underwrite margin, growth, and acquisition. Contract pharmacies and third-party administrators capture a share through fees. This heterogeneity is exactly what the transparency fight is about — and it is real.

Who is harmed if the spread disappears. If program value collapses — through the rebate model, Best Price stacking, use-of-funds restrictions, or manufacturer access limits — the first losers are safety-net providers and the patients and service lines they cross-subsidize: rural oncology, charity care, money-losing access points. The independent practices the statement wants to bring in would also find their new benefit smaller than expected if the spread is shrinking at the same time. And here is the part most often missed: eliminating the spread does not automatically lower what patients pay. Unless reforms force discounts through to patients at the point of care, the recovered value reverts to manufacturers as higher net — a transfer from providers to industry with no patient benefit at all.

That exposes the question the statement never asks: is the goal to redirect the spread (to patients and to verifiable safety-net use) or to shrink it (manufacturer net recovery)? Those are different objectives with different winners. ASCO's package leans toward policing the spread within the provider, yet several of its mechanics — and the manufacturer-backed rebate model it opposes — would shrink it, benefiting manufacturers rather than patients absent a pass-through mandate. Commercial payers, employers, and state Medicaid programs, who fund the largest share of the spread and have the most direct interest in where it lands, are absent from the statement entirely. A reform conversation that leaves them out cannot honestly claim to be about patient benefit.

A note on authorship and evidence

In the interest of full transparency: the statement's author panel is drawn heavily from community oncology, and the published conflict-of-interest disclosures include equity in an independent-practice platform and extensive pharmaceutical consulting relationships. None of that invalidates the analysis, but a document whose central recommendation extends 340B to independent practices warrants weighting accordingly. Likewise, several of the empirical claims about hospital charity care rely on analyses whose methodology is actively contested. Readers should treat the statement as one well-argued position in a live policy debate, not a settled consensus.

Bottom line

The updated statement is more sophisticated, and more consequential, than its abstract suggests. The problems it names are real, and on patient scope, contract pharmacy, and orphan drugs it deserves support. But the remedy is the wrong one on two counts. First, its most consequential standards — "appropriate use," "direct patient care," "demonstrably benefit," "underserved populations" — are undefined and wired to penalties and personal attestation, which turns compliance into guesswork and invites discretionary enforcement. Second, and with the longest tail, the statement is not attacking hospital eligibility today; it is constructing the intellectual framework that future reformers could apply to hospital outpatient departments tomorrow. The capital-expenditure restriction is this year's fight; the eligibility framework is the next decade's. And the context the statement omits entirely — the gross-to-net, Best Price, biosimilar, and site-of-care mechanics that actually govern where program value comes from and where it goes — is what any serious reform conversation has to start from.

Sources

Independent analysis. No outside funding; views are the author's own and do not represent any employer or client.

Girish Kaimal
Next

Healthcare Updates 06/01/2026